GlassScriptPhysician profile
Cristina Boccalandro
NPI 1508890427
$21,259.27
in general payments reported to CMS, 2019-2025
61 companies · $2,835 in 2025
The $2,835 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,766 · 2020: $3,665 · 2021: $2,992 · 2022: $2,679 · 2023: $2,265 · 2024: $2,058 · 2025: $2,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,016 · Education: $82.70 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,015.56 |
| Education | $82.70 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,430.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,975.28 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $1,524.26 | 2019-2025 | Freestyle Libre |
| Lilly USA, LLC | $1,465.92 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $743.19 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $653.37 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $580.32 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $577.84 | 2019-2025 | Unithroid |
| Abbvie INC. | $574.37 | 2019-2025 | Synthroid |
| Radius Health, INC. | $545.49 | 2019-2025 | Tymlos |
| Tandem Diabetes Care, INC. | $514.00 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $469.71 | 2019-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.43 | 2019-2025 | Jardiance |
| Ibsa Pharma INC. | $454.27 | 2019-2025 | Licart, Tirosint, Flector |
| Insulet Corporation | $420.94 | 2019-2025 | Omnipod |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $379.25 | 2025 | |
| Medtronic Minimed, INC. | $331.31 | 2019-2020 | |
| Companion Medical, INC. | $330.11 | 2019-2020 | |
| Antares Pharma, INC. | $326.09 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Mannkind Corporation | $316.66 | 2019-2024 | Afrezza |
| Amarin Pharma, INC. | $299.79 | 2019-2021 | |
| Horizon Therapeutics Plc | $270.24 | 2021-2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $252.84 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $236.48 | 2019-2023 | Steglatro |
| Medtronic, INC. | $220.72 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Astellas Pharma US INC | $196.80 | 2023-2025 | Veozah |
| Esperion Therapeutics, INC. | $184.84 | 2020-2024 | Nexletol |
| Beta Bionics, INC. | $173.60 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Zealand Pharma US, INC. | $163.61 | 2020-2022 | |
| Pfizer INC. | $160.24 | 2019-2022 | |
| Valeritas, INC. | $158.35 | 2019 | |
| Abiomed | $142.16 | 2020 | |
| Cequr Corporation | $127.37 | 2022-2025 | Cequr Simplicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.07 | 2020-2023 | Cycloset |
| Currax Pharmaceuticals LLC | $120.04 | 2019-2025 | Contrave |
| Sequel Med Tech, LLC | $104.14 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $97.21 | 2022-2025 | Gvoke Hypopen |
| Avvisto Therapeutics, LLC | $92.12 | 2025 | Cycloset |
| Shire North American Group INC | $91.36 | 2019 | |
| Ascendis Pharma Endocrinology INC | $81.84 | 2025 | Yorvipath |
| Tolmar, INC. | $81.52 | 2023-2025 | Jatenzo |
| Acella Pharmaceuticals, LLC | $71.78 | 2024-2025 | NP Thyroid 60 |
| Endo Pharmaceuticals INC. | $67.68 | 2019-2022 | |
| Vivus LLC | $67.32 | 2019-2022 | |
| Optinose US, INC. | $65.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $62.56 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $60.01 | 2019 | |
| Madrigal Pharmaceuticals | $48.59 | 2025 | Rezdiffra |
| Halozyme INC | $38.91 | 2023 | |
| Alexion Pharmaceuticals, INC. | $36.06 | 2020-2021 | |
| Gilead Sciences, INC. | $31.83 | 2019 | |
| Recordati_rare_diseases_inc. | $31.69 | 2020-2023 | Signifor Lar, Isturisa |
| Acerus Pharmaceuticals Corporation | $30.62 | 2020-2022 | |
| Nalpropion Pharmaceuticals LLC | $29.24 | 2019 | |
| Grt US Holding, INC. | $28.75 | 2021 | |
| Soleno Therapeutics, INC. | $26.98 | 2025 | Vykat Xr |
| Regeneron Healthcare Solutions, INC. | $21.96 | 2019 | |
| Alvogen INC | $21.51 | 2025 | Teriparatide |
| Eisai INC. | $21.27 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $21.20 | 2020 | |
| Vertical Pharmaceuticals, LLC | $19.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristina Boccalandro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.